Lowest Price Guaranteed From USD 3,999
Published
August 2019
Pages
580
View Count
5052
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
CAR-T cell therapies are based on the principle of harnessing the innate potential of the immune system to selectively target and destroy diseased cells. Encouraging clinical results reported across several completed and ongoing trials, coupled to lucrative financing, have inspired many biopharmaceutical developers and academic research groups to focus their efforts on this relatively novel class of cell-based immunotherapies. With two approved products, namely KYMRIAH® (Novartis) and YESCARTA® (Gilead Sciences), CAR-T cell therapies are presently considered among the most promising anticancer therapeutics available, with potential applications in treating other diseases as well. It is worth highlighting that 66% of the pipeline therapies are presently in the clinical stage.
Over 100 companies and 85 academic / research institutes are actively involved therapy development initiatives in this domain. The ongoing research activity in this domain has led to the discovery of several novel molecular targets, which can be exploited for cell therapy development. Further research and characterization of these targets has significantly strengthened the pipelines of stakeholder entities engaged in this market. Driven by the availability of innovative technology platforms, the CAR-T therapies market is poised for success in the long-run as several therapeutic leads have recently entered mid to late-stage (phase II and above) trials and are anticipated to enter the market over the next 5-10 years.
The “CAR-T Therapies Market, 2019-2030 (2nd edition)” report features an extensive study of the current market landscape and the future potential of CAR-T cell therapies. The report highlights the efforts of both industry players and academic organizations working in this domain. Amongst other elements, the report features the following:
One of the key objectives of the report was to estimate the existing market size and identify potential growth opportunities for CAR-T cell therapies over the coming decade. Based on several parameters, such as target consumer segments, region specific adoption rates and expected prices of such therapies, we have provided an informed estimate on the likely evolution of the market over the period 2019-2030. The report includes potential sales forecasts of CAR-T cell therapies that are currently marketed or are in late stages of development. Additionally, it provides forecasts for the overall CAR-T cell therapy market, wherein both the current and upcoming opportunity is segmented across [A] target indications (acute lymphoblastic leukemia, non-Hodgkin’s lymphoma, multiple myeloma, chronic lymphocytic leukemia, hepatocellular carcinoma and colorectal cancer), [B] important target antigens (CD19, BCMA, GPC3 and EGFR) and [C] key geographical regions (North America, Europe and Asia Pacific). To account for the uncertainties associated with the development of these novel therapies and to add robustness to our model, we have provided three forecast scenarios, portraying the conservative, base and optimistic tracks of the market’s evolution.
The opinions and insights presented in this study were influenced by discussions conducted with several key players in this domain. The report features detailed transcripts of interviews held with the following individuals (in alphabetical order of company names):
All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.
Chapter 2 provides an executive summary of the insights captured during our research. It offers a high-level view on the likely evolution of the CAR-T cell therapy market in the short to mid-term and long term.
Chapter 3 provides a general overview of CAR-T cell therapies. In this section, we have briefly discussed the conventional forms of therapy that are being used for the treatment of various oncological indications. Further, it includes a discussion on the advent and historical evolution of cancer immunotherapy, general manufacturing procedure of CAR-T cell therapies, factors supporting the growing popularity of CAR-T cell therapies and the challenges associated with such therapies.
Chapter 4 provides insights on the popularity of CAR-T cell therapies on the social media platform, Twitter. The section highlights the yearly distribution of tweets posted on the platform in the time period 2012-2019, and the most significant events responsible for increase in the volume of tweets each year. Additionally, the chapter highlights the most frequently talked about product candidates, popular disease indications, target antigens, and prolific authors and social media influencers.
Chapter 5 provides information on close to 500 CAR-T cell therapies that are currently approved or are in different stages of development (clinical and preclinical / discovery). It features a comprehensive analysis of pipeline molecules with respect to the type of developer(s), phase of development, target therapeutic area(s) and indication(s), key target antigen(s), source of T-cells (autologous / allogenic), route of administration, type of therapy (monotherapy / combination therapy) and patient segment. Further, the chapter features the most active players (in terms of number of pipeline candidates).
Chapter 6 presents a collection of key insights derived from the study. It includes a bubble analysis, highlighting the most popular targets of CAR-T cell therapies in hematological cancer and solid tumor space. To offer due credit to the work of eminent researchers in this domain, we have mapped the presence of key opinion leaders (who are involved in this field of research) across the globe. In addition, we have presented an analysis of the CAR constructs being used in the clinical CAR-T therapies on the basis of generation of CAR-T therapy, type of binding domain, type of vector and type of co-stimulatory domain.
Chapter 7 presents an analysis of the CAR-T clinical trials registered across the world, between 2009 and 2019, highlighting the year wise trend and the distribution across different geographies. In addition, we have provided a detailed list of factors that have influenced the growth of CAR-T therapies market in China.
Chapter 8 provides detailed profiles of marketed and mid to late stage CAR-T therapies (phase I/II or above). Each profile features an overview of the therapy, its mechanism of action, dosage information, details on the cost and sales information (wherever available), clinical development plan and key clinical trial results.
Chapter 9 identifies the most commonly targeted therapeutic indications, including hematological cancers and solid tumors and features brief discussions on the CAR-T cell therapies being developed against them. The section also highlights key epidemiological facts and the currently available treatment options for each indication.
Chapter 10 provides a list of technology platforms that are either available in the market or are being designed for the development of CAR-T cell therapies. A detailed discussion on innovative technology platforms that are being used for the development of CAR-T cell therapies, along with profiles of key technology providers. Further, it includes a competitiveness analysis of different CAR-T-based gene editing platforms, based on various parameters, such as ease of system design, cost of technology, level of toxicity and efficiency of technology.
Chapter 11 provides insights on cell therapy manufacturing, highlighting the current challenges that exist in this domain, and the pre-requisites for owning and maintaining cell therapy manufacturing sites. It includes a list of various cell therapy manufacturers, covering both contract manufacturing organizations and companies with in-house manufacturing capabilities. For the players mentioned in the chapter, we have included details on location of various manufacturing facilities, the products being manufactured, scale of operation and compliance to cGMP standards.
Chapter 12 highlights our views on the various factors that must be taken into consideration while deciding the prices of cell-based therapies. It features discussions on different models / approaches that a pharmaceutical company may choose to follow to decide the price at which their CAR-T cell therapy product can be marketed. Additionally, we have provided a brief overview of the reimbursement consideration for CAR-T cell therapies and a case study on the National Institute for Health and Care Excellence (NICE) appraisal of CAR-T therapy.
Chapter 13 features an elaborate discussion on the future commercial opportunity offered by CAR-T cell therapies. It provides a comprehensive market forecast analysis for molecules that are approved or are in different phases of development (phase I/II and above), taking into consideration the target patient population, existing / future competition, likely adoption rates and the likely price of different therapies. The chapter also presents a detailed market segmentation on the basis of [A] target indications (acute lymphoblastic leukemia, non-Hodgkin’s lymphoma, multiple myeloma, chronic lymphocytic leukemia, hepatocellular carcinoma and colorectal cancer), [B] important target antigens (CD19, BCMA, GPC3 and EGFR) and [C] key geographical regions (North America, Europe and Asia Pacific).
Chapter 14 highlights the key promotional strategies that are being implemented by the developers of the marketed products, KYMRIAH® and YESCARTA®. The promotional aspects covered in the chapter include details that are provided on the product website (covering key messages for patients and healthcare professionals), patient support offerings and informative downloadable content.
Chapter 15 includes brief company profiles of the leading players in the CAR-T cell therapy market. Each company profile includes an overview of the developer and brief description of the product portfolio specific to CAR-T cell therapies, technology portfolio (if available), recent developments related to CAR-T cell therapies and manufacturing capabilities of the companies. Additionally, we have provided details of the strategic / venture capital investments made in these companies.
Chapter 16 is a summary of the overall report. In this chapter, we have provided a list of key takeaways from the report, and expressed our independent opinion related to the research and analysis described in the previous chapters.
Chapter 17 is a collection of transcripts of interviews conducted with key stakeholders in the market. In this chapter, we have presented the details of our conversations with Tim Oldham (Chief Executive Officer, Cell Therapies), Vincent Brichard (Vice President, Immuno-Oncology, Celyad), Xian-Bao Zhan (Professor of Medicine and Director, Department of Oncology, Changhai Hospital), Troels Jordansen (Chief Executive Officer, Glycostem Therapeutics), Wei (William) Cao (Chief Executive Officer, Gracell Biotechnologies), Adrian Bot (Vice President, Scientific Affairs, Kite Pharma), Aino Kalervo (Competitive Intelligence Manager, Strategy & Business Development, Theravectys), Miguel Forte (Chief Operating Officer, TxCell), Enkhtsetseg Purev (Assistant Professor of Medicine, University of Colorado) and Brian Dattilo (Manager of Business Development, Waisman Biomanufacturing).
Chapter 18 is an appendix, which provides tabulated data and numbers for all the figures included in the report.
Chapter 19 is an appendix, which contains the list of companies and organizations mentioned in the report.
1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Chapter Outlines
2. EXECUTIVE SUMMARY
3. INTRODUCTION
3.1. Chapter Overview
3.2. Pillars of Cancer Therapy
3.3. Overview of Immunotherapies
3.4. Fundamentals of Cancer Immunotherapy
3.5. Classification of Cancer Immunotherapies
3.5.1. By Mechanism of Action
3.5.1.1. Active Immunotherapy
3.5.1.2. Passive Immunotherapy
3.5.2. By Type of Target
3.5.3. By Approach
3.5.3.1. Activation and Suppression Immunotherapy
3.5.4. By Product Class
3.5.4.1. Monoclonal Antibodies
3.5.4.2. Bispecific Antibodies
3.5.4.3. Cytokines
3.5.4.4. Oncolytic Virus Therapy
3.5.4.5. Therapeutic Cancer Vaccines
3.5.4.6. Cell-based Therapies
3.6. T-Cell Immunotherapies
3.6.1. Historical Evolution
3.6.2. Key Considerations for Developing T-Cell Immunotherapies
3.6.3. Strategies Employed for the Redirection of T-Cells
3.6.4. Manufacturing of Engineered T-Cells
3.6.5. T-Cell Transduction and Transfection Methods
3.6.5.1. Retroviral Vectors
3.6.5.2. Lentiviral Vectors
3.6.5.3. Non-viral Transfection Methods
3.7. Chimeric Antigen Receptor T-Cell Therapy (CAR-T)
3.7.1. History of Development
3.7.2. Anatomical Layout of CAR
3.7.2.1. Ectodomain
3.7.2.2. Transmembrane (TM) Domain
3.7.2.3. Endodomain
3.7.3. Development of CAR-T Cells
3.7.4. Universal CAR-T Cells
3.7.5. Route of Administration of CAR-T Cell Therapies
3.7.6. Case Study: CD19 CAR-T Cell Therapies
3.7.6.1. Other Important Biological Targets for CAR Development
3.7.7. Challenges Associated with CAR-T Cell Therapies
3.7.7.1. Competitive Risks
3.7.7.2. Clinical Risks
3.7.7.3. Regulatory Risks
3.7.7.4. Commercial Risks
4. EMERGING TRENDS ON SOCIAL MEDIA
4.1. Chapter Overview
4.2. CAR-T Cell Therapies: Trends on Twitter
4.2.1. Historical Trend in Volume of Tweets
4.2.2. Trending Words / Phrases on Twitter
4.2.3. Most Popular Drugs on Twitter
4.2.4. Most Prolific Authors on Twitter
4.2.5. Most Popular Indications and Target Antigens
5. MARKET LANDSCAPE
5.1. Chapter Overview
5.2. CAR-T Cell Therapies: Overall Market Overview
5.2.1. Analysis by Type of Developer
5.2.2. Analysis by Phase of Development
5.2.3. Analysis by Popular Target Indications
5.2.4. Analysis by Popular Target Antigens
5.2.5. Analysis by Source of T-Cells
5.2.6. Analysis by Route of Administration
5.2.7. Analysis by Patient Segment
5.2.8. Analysis by Type of Therapy
5.2.9. Key Industry Players: Analysis by Number of Therapies in Development
5.2.10. Key Non-Industry Players: Analysis by Number of Therapies in Development
6. KEY INSIGHTS
6.1. Chapter Overview
6.2. CAR-T Cell Therapies: Competitive Analysis by Popular Target Antigens
6.2.1. Popular Targets Related to Hematological Malignancies
6.2.1.1. Competitive Landscape of CD19 CAR-T Cell Therapies
6.2.1.2. Clinical Trial Results of Prominent CD19 CAR-T Cell Therapies
6.2.1.3. Competitive Landscape of BCMA CAR-T Cell Therapies
6.2.1.4. Clinical Trial Results of Prominent BCMA CAR-T Cell Therapies
6.2.2. Popular Targets Related to Solid Tumors
6.2.2.1. Competitive Landscape of Meso CAR-T Cell Therapies
6.2.2.2. Clinical Trial Results of Prominent Meso CAR-T Cell Therapies
6.2.2.3. Competitive Landscape of GD2 CAR-T Cell Therapies
6.2.2.4. Clinical Trial Results of Prominent GD2 CAR-T Cell Therapies
6.3. CAR-T Cell Therapies: Key Opinion Leaders
6.3.1. CAR-T Cell Therapies: Most Prominent Key Opinion Leaders
6.4. CAR-T Cell Therapies: CAR Construct Analysis
6.4.1. Analysis by Generation of CAR
6.4.2. Analysis by Type of scFv Antibody
6.4.3. Analysis by Type of Vector
6.4.4. Analysis by Type of Co-Stimulatory Domain(s)
7. CLINICAL TRIAL ANALYSIS
7.1. Chapter Overview
7.2. CAR-T Cell Therapies: Clinical Trial Analysis
7.2.1. Methodology
7.2.2. Analysis by Trial Registration Year
7.2.3. Geographical Analysis by Number of Registered Trials
7.2.4. Case Study: CAR-T Cell Therapy Market in China
7.2.4.1. Factors Contributing to the Growth of CAR-T Cell Therapy Trials in China
8. CAR-T CELL THERAPY PROFILES
8.1. Chapter Overview
8.2. KYMRIAH® / Tisagenlecleucel / CTL019 (Novartis)
8.2.1. Therapy Overview
8.2.2. Current Development Status
8.2.3. Key Clinical Trial Results
8.2.4. Dosage Regimen, Price and Manufacturing
8.3. YESCARTA® / Axicabtagene Ciloleucel / KTE-C19 (Kite Pharma)
8.3.1. Therapy Overview
8.3.2. Current Development Status
8.3.3. Key Clinical Trial Results
8.3.4. Dosage Regimen, Price and Manufacturing
8.4. JCAR (Juno Therapeutics)
8.4.1. Therapy Overview
8.4.2. Current Development Status
8.4.3. Key Clinical Results
8.4.3.1. JCAR014
8.4.3.2. JCAR017
8.4.3.3. JCAR018
8.4.3.4. JCARH125
8.4.4. Dosage Regimen and Manufacturing
8.5. bb2121 (bluebird bio / Celgene)
8.5.1. Therapy Overview
8.5.2. Current Development Status
8.5.3. Key Clinical Trial Results
8.5.4. Dosage Regimen and Manufacturing
8.6. LCAR-B38M CAR-T (Nanjing Legend Biotech / Janssen Biotech)
8.6.1. Therapy Overview
8.6.2. Current Development Status
8.6.3. Key Clinical Trial Results
8.6.4. Dosage Regimen and Manufacturing
8.7. CD19 CAR-T Cell Therapy (Takara Bio)
8.7.1. Therapy Overview
8.7.2. Current Development Status
8.7.3. Key Clinical Trial Results
8.7.4. Dosage Regimen and Manufacturing
8.8. Dual Targeting CAR-T Cell therapies (Autolus)
8.8.1. Therapy Overview
8.8.2. Current Development Status
8.8.3. Key Clinical Trial Results
8.8.3.1. AUTO2
8.8.3.2. AUTO3
8.8.4. Dosage Regimen and Manufacturing
8.9. CAR-T Cell Therapies (Sinobioway Cell Therapy)
8.9.1. Therapy Overview
8.9.2. Current Development Status
8.9.3. Dosage Regimen and Manufacturing
9. KEY THERAPEUTIC AREAS FOR CAR-T CELL THERAPIES
9.1. Chapter Overview
9.2. Hematological Malignancies
9.2.1. Leukemia and Lymphoma
9.2.1.1. Leukemia: Introduction and Epidemiology
9.2.1.1.1. Acute Myeloid Leukemia (AML)
9.2.1.1.2. Chronic Myeloid Leukemia (CML)
9.2.1.1.3. Acute Lymphocytic Leukemia (ALL)
9.2.1.1.4. Chronic Lymphocytic Leukemia (CLL)
9.2.1.2. Lymphoma: Introduction and Epidemiology
9.2.1.3. Current Treatment Landscape
9.2.1.3.1. Targeted Therapies
9.2.1.4. CAR-T Cell Therapies and Affiliated Research Landscape
9.2.1.4.1. CAR-T Cell Therapies and Leukemia / Lymphoma
9.2.2. Multiple Myeloma
9.2.2.1. Introduction and Epidemiology
9.2.2.2. Current Treatment Landscape
9.2.2.3. CAR-T Cell Therapies and Affiliated Research Landscape
9.3. Solid Tumors
9.3.1. Metastatic Melanoma
9.3.1.1. Introduction and Epidemiology
9.3.1.2. Current Treatment Landscape
9.3.1.3. CAR-T Cell Therapies and Affiliated Research Landscape
9.3.2. Lung Cancer
9.3.2.1. Introduction and Epidemiology
9.3.2.2. Current Treatment Landscape
9.3.2.3. CAR-T Cell Therapies and Affiliated Research Landscape
9.3.3. Pancreatic Cancer
9.3.3.1. Introduction and Epidemiology
9.3.3.2. Current Treatment Landscape
9.3.3.3. CAR-T Cell Therapies and Affiliated Research Landscape
9.3.4. Liver Cancer
9.3.4.1. Current Treatment Landscape
9.3.4.2. CAR-T Cell Therapies and Affiliated Research Landscape
9.3.5. Breast Cancer
9.3.5.1. Introduction and Epidemiology
9.3.5.2. Current Treatment Landscape
9.3.5.3. CAR-T Cell Therapies and Affiliated Research Landscape
9.3.6. Ovarian Cancer
9.3.6.1. Introduction and Epidemiology
9.3.6.2. Current Treatment Landscape
9.3.6.3. CAR-T Cell Therapies and Affiliated Research Landscape
9.3.7. Bladder Cancer
9.3.7.1. Introduction and Epidemiology
9.3.7.2. Current Treatment Landscape
9.3.7.3. CAR-T Cell Therapies and Affiliated Research Landscape
9.3.8. Kidney Cancer
9.3.8.1. Introduction and Epidemiology
9.3.8.2. Current Treatment Landscape
9.3.8.3. CAR-T Cell Therapies and Affiliated Research Landscape
10. EMERGING TECHNOLOGIES
10.1. Chapter Overview
10.2. Genome Editing Technologies
10.2.1. Applications of Genome Editing Technologies
10.2.2. Emerging Technology Platforms for CAR-T Cell Therapy Development and Production
10.2.2.1. CRISPR / Cas9 System
10.2.2.1.1. Key Components and Function
10.2.2.1.2. Mechanism of Action
10.2.2.1.3. Targeting Efficiency and Challenges
10.2.2.1.4. Next-GEN CRISPR Technology
10.2.2.1.5. Technology Providers
10.2.2.1.5.1. Editas Medicine
10.2.2.1.5.2. Intellia Therapeutics
10.2.2.1.5.3. CRISPR Therapeutics
10.2.2.1.5.4. Beam Therapeutics
10.2.2.1.5.5. Gracell Biotechnologies
10.2.2.2. TALENs
10.2.2.2.1. Key Components and Function
10.2.2.2.2. Mechanism of Action
10.2.2.2.3. Advantages and Challenges
10.2.2.2.4. Technology Providers
10.2.2.2.4.1. Cellectis
10.2.2.2.4.2. Editas Medicine
10.2.2.3. megaTAL
10.2.2.3.1. Technology Providers
10.2.2.3.1.1. bluebird bio
10.2.2.4. Zinc Finger Nuclease
10.2.2.4.1. Technology Providers
10.2.2.4.1.1. Sangamo Therapeutics
10.2.3. Competitive Analysis: Gene Editing Platforms
10.3. Designing CAR-T Cell Therapies with Improved Characteristics
10.3.1. Technologies for Targeting Multiple Cancers
10.3.1.1. Antibody Coupled T-Cell Receptor
10.3.1.1.1. Unum Therapeutics
10.3.1.2. NKR-T Platform
10.3.1.2.1. Celyad
10.3.1.2.2. Glycostem
10.3.2. Technologies for Improved Safety
10.3.2.1. Armored CAR and EGFRt Technology
10.3.2.1.1. Juno Therapeutics
10.3.2.2. RheoSwitch Therapeutic System
10.3.2.2.1. Intrexon
10.3.2.3. Inducible Caspase 9 Safety Switch
10.3.2.3.1. Bellicum Pharmaceuticals
10.3.2.3.1.1. CaspaCIDe Technology
10.3.2.3.1.2. CIDeCAR Technology
10.3.2.3.1.3. GoCAR-T Technology
10.3.2.3. On-Off Switch, Multiple Companies
10.3.2.3.1. Inhibitory CAR (iCAR) (Juno Therapeutics)
10.3.2.3.2. On-Off Switch (Theravectys)
10.3.2.4. Other Technologies to Improve CAR-T Safety
10.3.3. Allogeneic Technologies
10.3.3.1. CIK CAR-T Cells (Formula Pharmaceuticals)
10.3.3.2. Allogeneic Platform (Celyad)
10.3.3.3. Allogeneic Platform (Cellectis)
11. CASE STUDY: CELL THERAPY MANUFACTURING
11.1. Chapter Overview
11.2. An Overview to Cell Therapy Manufacturing
11.3. Cell Therapy Manufacturing Models
11.3.1. Centralized Manufacturing Model
11.3.2. Decentralized Manufacturing Model
11.4. Scalability of Cell Therapy Manufacturing Processes
11.4.1. Scale-Up
11.4.2. Scale-out
11.5. Types of Cell Therapy Manufacturers
11.6. Key Challenges Related to Manufacturing Cell Therapies
11.7. Important Factors for Cell Therapy Manufacturing
11.7.1. Characterization
11.7.2. Cost of Goods
11.8. Automation of Cell Therapy Manufacturing Processes
11.9. Cell Therapy Manufacturing Supply Chain
11.10. Companies with In-House Capabilities
11.11. Contract Manufacturers
11.12. Regulatory Landscape
12. COST PRICE ANALYSIS
12.1. Chapter Overview
12.2. Factors Contributing to the High Price of Cell / Gene Therapies
12.3. Pricing Models for CAR-T Cell Therapies
12.3.1. Based on Associated Costs
12.3.2. Based on Availability of Competing Products
12.3.3. Based on Patient Segment
12.3.4. Based on the Opinions of Industry Experts
12.4. Reimbursement-related Considerations for CAR-T Cell Therapies
12.4.1. Case Study: The National Institute for Health and Care Excellence (NICE) Appraisal of CAR-T Therapies
13. MARKET SIZING AND OPPORTUNITY ANALYSIS
13.1. Chapter Overview
13.2. Scope and Limitations
13.3. Key Assumptions and Forecast Methodology
13.4. Overall CAR-T Cell Therapy Market, 2019-2030
13.4.1. CAR-T Cell Therapy Market: Distribution by Target Indication
13.4.2. CAR-T Cell Therapy Market: Distribution by Target Antigen
13.4.3. CAR-T Cell Therapy Market: Distribution by Key Players
13.4.4. CAR-T Cell Therapy Market: Distribution by Geography
13.4.5. Product Wise Sales Forecast
13.4.5.1. KYMRIAH® (Novartis)
13.4.5.1.1. Target Patient Population
13.4.5.1.2. Sales Forecast (USD Million)
13.4.5.1.3. Net Present Value
13.4.5.1.4. Value Creation Analysis
13.4.5.2. YESCARTA® (Gilead Sciences)
13.4.5.2.1. Target Patient Population
13.4.5.2.2. Sales Forecast (USD Million)
13.4.5.2.3. Net Present Value (USD Million)
13.4.5.2.4. Value Creation Analysis
13.4.5.3. bb2121 (bluebird bio / Celgene)
13.4.5.3.1. Target Patient Population
13.4.5.3.2. Sales Forecast (USD Million)
13.4.5.3.3. Net Present Value (USD Million)
13.4.5.3.4. Value Creation Analysis
13.4.5.4. LCAR-B38M CAR-T (Nanjing Legend Biotech / Janssen)
13.4.5.4.1. Target Patient Population
13.4.5.4.2. Sales Forecast (USD Million)
13.4.5.4.3. Net Present Value (USD Million)
13.4.5.4.4. Value Creation Analysis
13.4.5.5. MB-CART19.1 (Miltenyi Biotec)
13.4.5.5.1. Target Patient Population
13.4.5.5.2. Sales Forecast (USD Million)
13.4.5.5.3. Net Present Value (USD Million)
13.4.5.5.4. Value Creation Analysis
13.4.5.6. CD19 CAR-T (Sinobioway Cell Therapy)
13.4.5.6.1. Target Patient Population
13.4.5.6.2. Sales Forecast (USD Million)
13.4.5.6.3. Net Present Value (USD Million)
13.4.5.6.4. Value Creation Analysis
13.4.5.7. JCAR017 (Juno Therapeutics / Celgene / Wuxi AppTec)
13.4.5.7.1. Target Patient Population
13.4.5.7.2. Sales Forecast (USD Million)
13.4.5.7.3. Net Present Value (USD Million)
13.4.5.7.4. Value Creation Analysis
13.4.5.8. AUTO2 (Autolus)
13.4.5.8.1. Target Patient Population
13.4.5.8.2. Sales Forecast (USD Million)
13.4.5.8.3. Net Present Value (USD Million)
13.4.5.8.4. Value Creation Analysis
13.4.5.9. AUTO3 (Autolus)
13.4.5.9.1. Target Patient Population
13.4.5.9.2. Sales Forecast (USD Million)
13.4.5.9.3. Net Present Value (USD Million)
13.4.5.9.4. Value Creation Analysis
13.4.5.10. GPC3 CAR-T (Shanghai GeneChem)
13.4.5.10.1. Target Patient Population
13.4.5.10.2. Sales Forecast (USD Million)
13.4.5.10.3. Net Present Value (USD Million)
13.4.5.10.4. Value Creation Analysis
13.4.5.11. BCMA CAR-T (The Pregene ShenZhen Biotechnology)
13.4.5.11.1. Target Patient Population
13.4.5.11.2. Sales Forecast (USD Million)
13.4.5.11.3. Net Present Value (USD Million)
13.4.5.11.4. Value Creation Analysis
13.4.5.12. CD19 CAR-T (The Pregene (ShenZhen) Biotechnology)
13.4.5.12.1. Target Patient Population
13.4.5.12.2. Sales Forecast (USD Million)
13.4.5.12.3. Net Present Value (USD Million)
13.4.5.12.4. Value Creation Analysis
13.4.5.13. CD19 CAR-T (Shanghai Bioray Laboratory)
13.4.5.13.1. Target Patient Population
13.4.5.13.2. Sales Forecast (USD Million)
13.4.5.13.3. Net Present Value (USD Million)
13.4.5.13.4. Value Creation Analysis
13.4.5.14. Humanized CD19 CAR-T (Shanghai Unicar-Therapy Bio-medicine Technology)
13.4.5.14.1. Target Patient Population
13.4.5.14.2. Sales Forecast (USD Million)
13.4.5.14.3. Net Present Value (USD Million)
13.4.5.14.4. Value Creation Analysis
13.4.5.15. PCAR-019 (PersonGen BioTherapeutics)
13.4.5.15.1. Target Patient Population
13.4.5.15.2. Sales Forecast (USD Million)
13.4.5.15.3. Net Present Value (USD Million)
13.4.5.15.4. Value Creation Analysis
13.4.5.16. TBI-1501 (Takara Bio)
13.4.5.16.1. Target Patient Population
13.4.5.16.2. Sales Forecast (USD Million)
13.4.5.16.3. Net Present Value (USD Million)
13.4.5.16.4. Value Creation Analysis
13.4.5.17. IM19 CAR-T Cell Therapy (Beijing Immunochina Medical Science &
Technology)
13.4.5.17.1. Target Population
13.4.5.17.2. Sales Forecast (USD Million)
13.4.5.17.3. Net Present Value (USD Million)
13.4.5.17.4. Value Creation Analysis
13.4.5.18. CCT301 CAR-T Cell Therapy (Shanghai Sinobioway Sunterra Biotech)
13.4.5.18.1. Target Patient Population
13.4.5.18.2. Sales Forecast (USD Million)
13.4.5.18.3. Net Present Value (USD Million)
13.4.5.18.4. Value Creation Analysis
13.4.5.19. BinD19 (Shenzhen BinDeBio)
13.4.5.19.1. Target Patient Population
13.4.5.19.2. Sales Forecast (USD Million)
13.4.5.19.3. Net Present Value (USD Million)
13.4.5.19.4. Value Creation Analysis
13.4.5.20. CARCIK-CD19 (Formula Pharmaceuticals)
13.4.5.20.1. Target Patient Population
13.4.5.20.2. Sales Forecast (USD Million)
13.4.5.20.3. Net Present Value (USD Million)
13.4.5.20.4. Value Creation Analysis
13.4.5.21. EGFR CART Cell Therapy (The Beijing Pregene Science and Technology)
13.4.5.21.1. Target Patient Population
13.4.5.21.2. Sales Forecast (USD Million)
13.4.5.21.3. Net Present Value (USD Million)
13.4.5.21.4. Value Creation Analysis
13.4.5.22. Anti-MUC1 CAR-T Cell Therapy (Guangzhou Anjie Biomedical Technology)
13.4.5.22.1. Target Patient Population
13.4.5.22.2. Sales Forecast (USD Million)
13.4.5.22.3. Net Present Value (USD Million)
13.4.5.22.4. Value Creation Analysis
14. PROMOTIONAL ANALYSIS
14.1. Chapter Overview
14.2. Channels Used for Promotional Campaigns
14.3. Summary of Product Website Analysis
14.4. Summary of Patient Support Services and Informative Downloads
14.5. KYMRIAH®: Promotional Analysis
14.5.1. Drug Overview
14.5.2. Product Website Analysis
14.5.2.1. Messages for Healthcare Professionals
14.5.2.2. Messages for Patients
14.5.3. Patient Support Services and Informative Downloads
14.5.4. Other Promotional Activities
14.5.4.1. Presence in Conferences
14.6. YESCARTA®: Promotional Analysis
14.6.1. Drug Overview
14.6.2. Product Website Analysis
14.6.2.1. Messages for Healthcare Professionals
14.6.2.3. Messages for Patients
14.6.3. Patient Support Services and Informative Downloads
14.6.4. Other Promotional Activities
14.6.4.1. Presence in Conferences
15. COMPANY PROFILES
15.1. Chapter Overview
15.2. Autolus
15.3. bluebird bio
15.4. CARsgen Therapeutics
15.5. Celgene
15.6. Cell Medica
15.7. Cellectis
15.8. Cellular Biomedicine Group
15.9. Innovative Cellular Therapeutics
15.10. Kite Pharma (A Gilead Sciences Company)
15.11. Noile-Immune Biotech
15.12. Novartis
15.13. Shanghai GeneChem
15.14. Sinobioway Cell Therapy
15.15. Takara Bio
15.16. ZIOPHARM Oncology
16. CONCLUDING REMARKS
16.1. Chapter Overview
16.2. Key Takeaways
17. EXECUTIVE INSIGHTS
17.1. Chapter Overview
17.2. Cell Therapies
17.2.1. Interview Transcript: Tim Oldham, Chief Executive Officer
17.3. Celyad
17.3.1. Interview Transcript: Vincent Brichard, Vice President, Immuno-Oncologys
17.4. Changhai Hospital
17.4.1. Interview Transcript: Xian-Bao Zhan, Professor of Medicine and Director, Department of Oncology
17.5. Glycostem Therapeutics
17.5.1. Interview Transcript: Troels Jordansen, Chief Executive Officer
17.6. Gracell Biotechnologies
17.6.1. Interview Transcript: Wei (William) Cao, Chief Executive Officer
17.7. Kite Pharma
17.7.1. Interview Transcript: Adrian Bot, Vice President, Scientific Affairs
17.8. Theravectys
17.8.1. Interview Transcript: Aino Kalervo, Competitive Intelligence Manager, Strategy & Business Development
17.9. TxCell
17.9.1. Interview Transcript: Miguel Forte, Chief Operating Officer
17.10. University of Colorado
17.10.1. Interview Transcript: Enkhtsetseg Purev, Assistant Professor of Medicine
17.11. Waisman Biomanufacturing
17.11.1. Interview Transcript: Brian Dattilo, Manager of Business Development
18. APPENDIX 1: TABULATED DATA
19. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS
Figure 3.1. Pillars of Cancer Therapy
Figure 3.2. Differences between Active and Passive Immunotherapies
Figure 3.3. Differences between Specific and Non-Specific Immunotherapies
Figure 3.4. Strategies Employed for the Redirection of T-Cells
Figure 3.5. T-Cell Manufacturing: General Procedure
Figure 3.6. Historical Development of CAR-T cells
Figure 3.7. Structure of Chimeric Antigen Receptor
Figure 3.8. Chimeric Antigen Receptors: Structural Variations across Different Generations
Figure 3.9. CAR-T Cell Therapies: Development Process
Figure 3.10. Challenges Associated with CAR-T Cell Therapies
Figure 4.1. Social Media Analysis: Historical Trend on Twitter, January 2012-April 2019
Figure 4.2. Social Media Analysis: Trending Words / Phrases on Twitter
Figure 4.3. Social Media Analysis: Most Popular Drug Candidates on Twitter
Figure 4.4. Social Media Analysis: Most Prolific Authors on Twitter
Figure 4.5. Average Number of Likes, Re-tweets and Comments Related to CAR-T Cell Therapies
Figure 4.6. Social Media Analysis: Most Popular Indications and Target Antigen
Figure 5.1. CAR-T Cell Therapies: Analysis by Type of Developer
Figure 5.2. CAR-T Cell Therapies: Analysis by Phase of Development
Figure 5.3. CAR-T Cell Therapies: Analysis by Target Therapeutic Area
Figure 5.4. CAR-T Cell Therapies: Analysis by Popular Target Indications
Figure 5.5. CAR-T Cell Therapies: Analysis by Popular Target Antigens
Figure 5.6. CAR-T Cell Therapies: Analysis by Source of T-Cells
Figure 5.7. CAR-T Cell Therapies: Analysis by Route of Administration
Figure 5.8. CAR-T Cell Therapies: Analysis by Patient Segment
Figure 5.9. CAR-T Cell Therapies: Analysis by Type of Therapy
Figure 5.10. CAR-T Cell Therapies: Active Industry Players by Number of Therapies in Clinical Development
Figure 5.11. CAR-T Cell Therapies: Active Industry Players by Number of Therapies in Preclinical Development
Figure 5.12. CAR-T Cell Therapies: Active Non-Industry Players by Number of Therapies in Clinical Development
Figure 5.13. CAR-T Cell Therapies: Active Non-Industry Players by Number of Therapies in Preclinical Development
Figure 6.1. CAR-T Cell Therapies: Popular Targets in Hematological Malignancies
Figure 6.2. CAR-T Cell Therapies: Popular Targets in Solid Tumor
Figure 6.3. CAR-T Cell Therapies: Geographical Distribution of Key Opinion Leaders
Figure 6.4. CAR-T Cell Therapies: Prominent Key Opinion Leaders
Figure 6.5. CAR-Construction: Analysis by Generation of CAR-T Therapies
Figure 6.6. CAR-Construction: Analysis by Type of scFv Antibody used in CAR-T Therapies
Figure 6.7. CAR-Construction: Analysis by Type of Vector
Figure 6.8. CAR-Construction: Analysis by Type of Co-Stimulatory Domain(s)
Figure 7.1. CAR-T Cell Therapy Clinical Trials: Distribution by Trial Registration Year
Figure 7.2. CAR-T Cell Therapy Clinical Trials: Distribution by Number of Clinical Trials and Geography (Pre-2016 and 2016-2019)
Figure 8.1. Manufacturing of CD19 CAR-T Cells: Process Comparison
Figure 9.1. Leukemia: Classification
Figure 9.2. Leukemia: Global Epidemiological Distribution
Figure 9.3. Lymphoma: Global Epidemiological Distribution
Figure 9.4. Multiple Myeloma: Global Epidemiological Distribution
Figure 9.5. Melanoma: Global Epidemiological Distribution
Figure 9.6. Lung Cancers: Classification
Figure 9.7. Lung Cancer: Global Epidemiological Distribution
Figure 9.8. Pancreatic Cancer: Global Epidemiological Distribution
Figure 9.9. Liver Cancer: Global Epidemiological Distribution
Figure 9.10. Breast Cancer: Global Epidemiological Distribution
Figure 9.11. Ovarian Cancer: Global Epidemiological Distribution
Figure 9.12. Bladder Cancer: Global Epidemiological Distribution
Figure 9.13. Kidney Cancer: Global Epidemiological Distribution
Figure 10.1. Genome Editing Technologies: Applications
Figure 10.2. Genome Editing: Emerging Technology Platforms Used in CAR-T Cell Therapies
Figure 10.3. Competitiveness Analysis: Gene Editing Platforms
Figure 10.4. CAR-T Cell Therapies: Key Technologies to Enhance Features / Characteristics
Figure 10.5. Cellectis: Properties of Enhanced T-Cell Platform
Figure 10.6. Cellectis: Allogenic CAR-T Platform, Comparison with Autologous CAR-T Platform
Figure 11.1. Steps for Manufacturing Cell Therapies
Figure 11.2. Centralized Manufacturing: Process Model
Figure 11.3. Decentralized Manufacturing: Process Model
Figure 11.4. Cell Therapy Manufacturing: Types of Manufacturers
Figure 11.5. Cell Therapy: Challenges and Drivers
Figure 11.6. Cell Therapies: Potency as Critical Quality Attribute
Figure 11.7. Cell Therapy Manufacturing: Supply Chain Model
Figure 11.8. Cell Therapy Manufacturing: Supply Chain Risk Assessment Considerations
Figure 12.1. Targeted Therapies: Pricing Model Based on Patient Segment
Figure 13.1. Overall CAR-T Cell Therapies Market, 2019-2030 (USD Billion)
Figure 13.2. CAR-T Cell Therapy Market: Distribution by Target Indication(s) (USD Billion)
Figure 13.3. CAR-T Cell Therapy Market: Distribution by Target Antigen(s) (USD Billion)
Figure 13.4. CAR-T Cell Therapy Market: Key Players (USD Billion)
Figure 13.5. CAR-T Cell Therapy Market: Distribution by Geography (USD Billion)
Figure 13.6. KYMRIAH® (Novartis): Current Status of Development
Figure 13.7. KYMRIAH® (Novartis) Sales Forecast, till 2030 (USD Million)
Figure 13.8. YESCARTA® (Gilead Sciences): Current Status of Development
Figure 13.9. YESCARTA® (Gilead Sciences) Sales Forecast, till 2030 (USD Million)
Figure 13.10. bb2121 (bluebird bio / Celgene): Current Status of Development
Figure 13.11. bb2121 (bluebird bio / Celgene) Sales Forecast, till 2030 (USD Million)
Figure 13.12. LCAR-B38M CAR-T (Nanjing Legend Biotech / Janssen): Current Status of Development
Figure 13.13. LCAR-B38M CAR-T (Nanjing Legend Biotech / Janssen) Sales Forecast, till 2030 (USD Million)
Figure 13.14. MB-CART19.1 (Miltenyi Biotec): Current Status of Development
Figure 13.15. MB-CART19.1 (Miltenyi Biotec) Sales Forecast, till 2030 (USD Million)
Figure 13.16. CD19 CAR-T (Sinobioway Cell Therapy): Current Status of Development
Figure 13.17. CD19 CAR-T (Sinobioway Cell Therapy) Sales Forecast, till 2030 (USD Million)
Figure 13.18. JCAR017 (Juno Therapeutics / Celgene / WuXi AppTec): Current Status of Development
Figure 13.19. JCAR017 (Juno Therapeutics / Celgene / WuXi AppTec) Sales Forecast, till 2030 (USD Million)
Figure 13.20. AUTO2 (Autolus): Current Status of Development
Figure 13.21. AUTO2 (Autolus) Sales Forecast, till 2030 (USD Million)
Figure 13.22. AUTO3 (Autolus): Current Status of Development
Figure 13.23. AUTO3 (Autolus) Sales Forecast, till 2030 (USD Million)
Figure 13.24. GPC3 CAR-T (Shanghai GeneChem): Current Status of Development
Figure 13.25. GPC3 CAR-T (Shanghai GeneChem) Sales Forecast, till 2030 (USD Million)
Figure 13.26. BCMA CAR-T (The Pregene (ShenZhen) Biotechnology): Current Status of Development
Figure 13.27. BCMA CAR-T (The Pregene (ShenZhen) Biotechnology) Sales Forecast, till 2030 (USD Million)
Figure 13.28. CD19 CAR-T (The Pregene (ShenZhen) Biotechnology): Current Status of Development
Figure 13.29. CD19 CAR-T (The Pregene (ShenZhen) Biotechnology) Sales Forecast, till 2030 (USD Million)
Figure 13.30. CD19 CAR-T (Shanghai Bioray Laboratory): Current Status of Development
Figure 13.31. CD19 CAR-T (Shanghai Bioray Laboratory) Sales Forecast, till 2030 (USD Million)
Figure 13.32. Humanized CD19 CAR-T (Shanghai Unicar-Therapy Bio-medicine Technology): Current Status of Development
Figure 13.33. Humanized CD19 CAR-T (Shanghai Unicar-Therapy Bio-medicine Technology, till 2030 (USD Million)
Figure 13.36. PCAR-019 (PersonGen BioTherapeutics): Current Status of Development
Figure 13.37. PCAR-019 (PersonGen BioTherapeutics) Sales Forecast, till 2030 (USD Million)
Figure 13.38. TBI-1501 (Takara Bio): Current Status of Development
Figure 13.39. TBI-1501 (Takara Bio) Sales Forecast, till 2030 (USD Million)
Figure 13.40. IM19 CAR-T Cell Therapy (Beijing Immunochina Medical Science & Technology): Current Status of Development
Figure 13.41. IM19 CAR-T Cell Therapy (Beijing Immunochina Medical Science & Technology) Sales Forecast, till 2030 (USD Million)
Figure 13.42. CCT301 CAR-T (Shanghai Sinobioway Sunterra Biotech): Current Status of Development
Figure 13.43. CCT301 CAR-T (Shanghai Sinobioway Sunterra Biotech) Sales Forecast, till 2030 (USD Million)
Figure 13.44. BinD19 (Shenzhen BinDeBio): Current Status of Development
Figure 13.45. BinD19 (Shenzhen BinDeBio) Sales Forecast, till 2030 (USD Million)
Figure 13.46. CARCIK-CD19 (Formula Pharmaceuticals): Current Status of Development
Figure 13.47. CARCIK-CD19 (Formula Pharmaceuticals) Sales Forecast, till 2030 (USD Million)
Figure 13.48. EGFR CART (The Beijing Pregene Science and Technology): Current Status of Development
Figure 13.49. EGFR CART (The Beijing Pregene Science and Technology) Sales Forecast, till 2030 (USD Million)
Figure 13.50. Anti-MUC1 CAR-T Cell Therapy (Guangzhou Anjie Biomedical Technology): Current Status of Development
Figure 13.51. Anti-MUC1 CAR-T Cell Therapy (Guangzhou Anjie Biomedical Technology) Sales Forecast, till 2030 (USD Million)
Figure 14.1. Channels Used for Promotional Campaigns
Figure 14.2. Promotional / Marketing Strategy: Product Website Analysis
Figure 14.3. Promotional / Marketing Strategy: Patient Support Services and Informative Downloads
Figure 14.4. Product Website Analysis: KYMRIAH®, Messages for Healthcare Professionals
Figure 14.5. Product Website Analysis: KYMRIAH®, Messages for Patients
Figure 14.6. Product Website Analysis: KYMRIAH®, Patient Support Program
Figure 14.7. KYMRIAH®, Presence in Conferences
Figure 14.8. Product Website Analysis: YESCARTA®, Messages for Healthcare Professionals
Figure 14.9. Product Website Analysis: YESCARTA®, Messages for Patients
Figure 14.10. Product Website Analysis: YESCARTA®, Kite Konnect
Figure 14.11. Product Website Analysis: YESCARTA®, Platform for Reporting Adverse Events / Products Complaints and Requesting Medical Information
Figure 14.12. YESCARTA®, Presence in Conferences
Figure 16.1. CAR-T Cell Therapy Market Landscape: Industry Participants
Figure 16.2. CAR-T Cell Therapy Market Landscape: Non-Industry Participants
Figure 16.3. CAR-T Cell Therapy Market Forecast, 2019, 2025 and 2030: Conservative, Base and Optimistic Scenarios (USD Billion)
Table 3.1. Types of Immunotherapies and Affiliated Mechanisms of Action
Table 3.2. FDA Approved Antibody based Cancer Therapeutics
Table 3.5. Key Characteristics of CAR-T Cells
Table 3.6. Comparison of First and Second-Generation CAR-Ts
Table 3.7. CD19 CAR-T Cells: Preclinical Results
Table 3.8. Other Targets under Clinical / Preclinical Studies for CAR-T Cell Therapies
Table 5.1. CAR-T Cell Therapies: Clinical Pipeline
Table 5.2. CAR-T Cell Therapies: Preclinical Pipeline
Table 6.1. CD19 CAR-T Cell Therapies: Competitive Landscape
Table 6.2. CD19 CAR-T Cell Therapies: Clinical Outcomes
Table 6.3. BCMA CAR-T Cell Therapies: Competitive Landscape
Table 6.4. BCMA CAR-T Cell Therapies: Clinical Outcomes
Table 6.5. Meso CAR-T Cell Therapies: Competitive Landscape
Table 6.6. Meso CAR-T Cell Therapies: Clinical Outcomes
Table 6.7. GD2 CAR-T Cell Therapies: Competitive Landscape
Table 6.8. GD2 CAR-T Cell Therapies: Clinical Outcomes
Table 6.9. CAR-T Cell Therapies: Principle Investigators
Table 6.10. CAR-T Therapies: Information on Constructs of Clinical Candidates
Table 7.1. CAR-T Cell Therapies: List of Clinical Trials
Table 7.2. Advanced Phase CAR-T Cell Therapies in China
Table 8.1. KYMRIAH®: Clinical Studies
Table 8.2. KYMRIAH®: Clinical Trial Endpoints (ALL)
Table 8.3. KYMRIAH®: Clinical Trial Endpoints (CLL / MM / NHL / FL)
Table 8.4. YESCARTA®: Clinical Studies
Table 8.5. YESCARTA®: Clinical Trial Endpoints
Table 8.6. JCAR Series: Molecules in Clinical Development
Table 8.7. JCAR: CAR-T Design
Table 8.8. JCAR014: Clinical Studies
Table 8.9. JCAR017: Clinical Studies
Table 8.10. JCAR018: Clinical Studies
Table 8.11. JCAR020: Clinical Studies
Table 8.12. JCAR023: Clinical Studies
Table 8.13. JCAR024: Clinical Studies
Table 8.14. JCARH125: Clinical Studies
Table 8.15. JCAR Series: Clinical Trial Endpoints (Phase I/II / Phase II / Phase III)
Table 8.16. JCAR Series: Clinical Trial Endpoints (Phase I)
Table 8.17. JCAR: Dosage Regimen
Table 8.18. bb2121: Clinical Studies
Table 8.19. bb2121: Clinical Trial Endpoints
Table 8.20. LCAR-B38M CAR-T: Clinical Studies
Table 8.21. LCAR-B38M CAR-T: Clinical Trial Endpoints
Table 8.22. Takara Bio’s CD19 CAR-T: Clinical Studies
Table 8.23. Takara Bio’s CD19 CAR-T: Clinical Trial Endpoints
Table 8.24. TBI-1501: Dosage Regimen
Table 8.25. AUTO2: Clinical Studies
Table 8.26. AUTO3: Clinical Studies
Table 8.27. Autolus’s Dual Targeting CAR-T Cell Therapies: Clinical Trial Endpoints
Table 8.28. Sinobioway Cell Therapy’s CD19 CAR-T Therapy: Clinical Studies
Table 8.29. Sinobioway Cell Therapy’s EPCAM CAR-T Therapy: Clinical Studies
Table 8.30. Sinobioway Cell Therapy’s Targeting CAR-T Cell Therapies: Clinical Trial Endpoints
Table 8.31. Phase I/II or Phase II CAR-T Cell Therapies from the Industry Players
Table 9.1. Comparison of Hodgkin’s and Non-Hodgkin’s Lymphoma
Table 9.2. Leukemia: List of Marketed Targeted Therapeutics
Table 9.3. Lymphoma: List of Marketed Targeted Therapeutics
Table 9.4. CAR-T Cell Therapies: Targets under Investigation for Leukemia
Table 9.5. CAR-T Cell Therapies: Targets under Investigation for Lymphoma
Table 9.6. Multiple Myeloma: List of Marketed Targeted Therapeutics
Table 9.7. CAR-T Cell Therapies: Targets under Investigation for Multiple Myeloma
Table 9.8. Melanoma: List of Marketed Targeted Therapeutics
Table 9.9. Lung Cancer: List of Marketed Targeted Therapeutics
Table 9.10. CAR-T Cell Therapies: Targets under Investigation for Lung Cancer
Table 9.11. Pancreatic Cancer: List of Marketed Targeted Therapeutics
Table 9.12. CAR-T Cell Therapies: Targets under Investigation for Pancreatic Cancer
Table 9.13. Liver Cancer: List of Marketed Targeted Therapeutics,
Table 9.14. CAR-T Cell Therapies: Targets under Investigation for Liver Cancer
Table 9.15. Breast Cancer: List of Marketed Targeted Therapeutics
Table 9.16. CAR-T Cell Therapies: Targets under Investigation for Breast Cancer
Table 9.17. Ovarian Cancer: List of Marketed Targeted Therapeutics
Table 9.18. CAR-T Cell Therapies: Targets under Investigation for Ovarian Cancer
Table 9.19. Bladder Cancer: List of Marketed Targeted Therapeutics
Table 9.20. Renal Cell Carcinoma: List of Marketed Targeted Therapeutics
Table 10.1. Editas Medicine: CRISPR / Cas9 Technology, Research Publications
Table 10.2. Editas Medicine: Funding Instances
Table 10.3. Editas Medicine: Collaborations
Table 10.4. Intellia Therapeutics: CRISPR / Cas9 Technology, Research Publications
Table 10.5. Intellia Therapeutics: Funding Instances
Table 10.6. Intellia Therapeutics: Collaborations
Table 10.7. CRISPR Therapeutics: CRIPSR / Cas9 Technology, Research Publications
Table 10.8. CRISPR Therapeutics: Funding Instances
Table 10.9. CRISPR Therapeutics: Collaborations
Table 10.10. Beam Therapeutics: Funding Instances
Table 10.11. Beam Therapeutics: Collaborations
Table 10.12. Gracell Biotechnologies: Funding Instances
Table 10.13. Cellectis: Funding Instances
Table 10.14. Cellectis: Collaborations
Table 10.15. bluebird bio: megaTAL Technology, Research Publications
Table 10.16. bluebird bio: Funding Instances
Table 10.17. bluebird bio: Collaborations
Table 10.18. Sangamo Therapeutics: Funding Instances
Table 10.19. Sangamo Therapeutics: Collaborations
Table 10.20. Unum Therapeutics: Funding Instances
Table 10.21. Unum Therapeutics: Collaborations
Table 10.22. Celyad: Funding Instances
Table 10.23. Celyad: Collaborations
Table 10.24. Glycostem: Funding Instances
Table 10.25. Glycostem: Collaborations
Table 10.26. Intrexon: Funding Instances
Table 10.27. Intrexon: Collaborations
Table 10.28. Bellicum Pharmaceuticals: Key Switch Technologies
Table 10.29. Bellicum Pharmaceuticals: Switch Technologies, Research Publications
Table 10.30. Bellicum Pharmaceuticals: Funding Instances
Table 10.31. Bellicum Pharmaceuticals: Collaborations
Table 10.32. Theravectys: Funding Instances
Table 10.33. Technologies For CAR-T Safety Enhancement
Table 10.34. Formula Pharmaceuticals: Collaborations
Table 11.1. Assessment Strategies for Different Manufacturing Processes
Table 11.2. Advantages and Disadvantages of Centralized and Decentralized Manufacturing Models
Table 11.3. Cell Therapy Manufacturing: Companies with In-house Capabilities
Table 11.4. Cell Therapy Manufacturing: Contract Manufacturers
Table 12.1. Price of Marketed Gene / Cell Therapies
Table 12.2. Price of Marketed Targeted Drugs
Table 12.3. CAR-T Cell Therapies: Expert Opinions on Pricing
Table 12.4. CAR-T Cell Therapies: Reimbursement Landscape
Table 13.1. CAR-T Cell Therapies: List of Forecasted Molecules
Table 13.2. KYMRIAH® (Novartis): Net Present Value (USD Million)
Table 13.3. KYMRIAH® (Novartis): Value Creation Analysis (USD Million)
Table 13.4. YESCARTA® (Gilead Sciences): Net Present Value (USD Million)
Table 13.5. YESCARTA® (Gilead Sciences): Value Creation Analysis (USD Million)
Table 13.6. bb2121 (bluebird bio / Celgene): Net Present Value (USD Million)
Table 13.7. bb2121 (bluebird bio / Celgene): Value Creation Analysis (USD Million)
Table 13.8. LCAR-B38M (Nanjing Legend Biotech / Janssen): Net Present Value (USD Million)
Table 13.9. LCAR-B38M (Nanjing Legend Biotech / Janssen): Value Creation Analysis (USD Million)
Table 13.10. MB-CART19.1 (Miltenyi Biotec): Net Present Value (USD Million)
Table 13.11. MB-CART19.1 (Miltenyi Biotec): Value Creation Analysis (USD Million)
Table 13.12. CD19 CAR-T (Sinobioway Cell Therapy): Net Present Value (USD Million)
Table 13.13. CD19 CAR-T (Sinobioway Cell Therapy): Value Creation Analysis (USD Million)
Table 13.14. JCAR017 (Juno Therapeutics / Celgene / WuXi AppTec): Net Present Value (USD Million)
Table 13.15. JCAR017 (Juno Therapeutics / Celgene / WuXi AppTec): Value Creation Analysis (USD Million)
Table 13.16. AUTO2 (Autolus): Net Present Value (USD Million)
Table 13.17. AUTO2 (Autolus): Value Creation Analysis (USD Million)
Table 13.18. AUTO3 (Autolus): Net Present Value (USD Million)
Table 13.19. AUTO3 (Autolus): Value Creation Analysis (USD Million)
Table 13.20. GPC3 CAR-T (Shanghai GeneChem): Net Present Value (USD Million)
Table 13.21. GPC3 CAR-T (Shanghai GeneChem): Value Creation Analysis (USD Million)
Table 13.22. BCMA CAR-T (The Pregene (ShenZhen) Biotechnology): Net Present Value (USD Million)
Table 13.23. BCMA CAR-T (The Pregene (ShenZhen) Biotechnology): Value Creation Analysis (USD Million)
Table 13.24. CD19 CAR-T (The Pregene (ShenZhen) Biotechnology): Net Present Value (USD Million)
Table 13.25. CD19 CAR-T (The Pregene (ShenZhen) Biotechnology): Value Creation Analysis (USD Million)
Table 13.26. CD19 CAR-T (Shanghai Bioray Laboratory): Net Present Value (USD Million)
Table 13.27. CD19 CAR-T (Shanghai Bioray Laboratory): Value Creation Analysis (USD Million)
Table 13.28. Humanized CD19 CAR-T (Shanghai Unicar-Therapy Bio-medicine Technology): Net Present Value (USD Million)
Table 13.29. Humanized CD19 CAR-T (Shanghai Unicar-Therapy Bio-medicine Technology): Value Creation Analysis (USD Million)
Table 13.30. PCAR-019 (PersonGen BioTherapeutics): Net Present Value (USD Million)
Table 13.31. PCAR-019 (PersonGen BioTherapeutics): Value Creation Analysis (USD Million)
Table 13.32. TBI-1501 (Takara Bio): Net Present Value (USD Million)
Table 13.33. TBI-1501 (Takara Bio): Value Creation Analysis (USD Million)
Table 13.34. IM19 CAR-T Cell Therapy (Beijing Immunochina Medical Science & Technology): Net Present Value (USD Million)
Table 13.35. IM19 CAR-T Cell Therapy (Beijing Immunochina Medical Science & Technology): Value Creation Analysis (USD Million)
Table 13.36. CCT301 CAR-T (Shanghai Sinobioway Sunterra Biotech): Net Present Value (USD Million)
Table 13.37. CCT301 CAR-T (Shanghai Sinobioway Sunterra Biotech): Value Creation Analysis (USD Million)
Table 13.38. BinD19 (Shenzhen BinDeBio): Net Present Value (USD Million)
Table 13.39. BinD19 (Shenzhen BinDeBio): Value Creation Analysis (USD Million)
Table 13.40. CARCIK-CD19 (Formula Pharmaceuticals): Net Present Value (USD Million)
Table 13.41. CARCIK-CD19 (Formula Pharmaceuticals): Value Creation Analysis (USD Million)
Table 13.42. EGFR CART (The Beijing Pregene Science and Technology): Net Present Value (USD Million)
Table 13.43. EGFR CART (The Beijing Pregene Science and Technology): Value Creation Analysis (USD Million)
Table 13.44. Anti-MUC1 CAR-T Cell Therapy (Guangzhou Anjie Biomedical Technology): Net Present Value (USD Million)
Table 13.45. Anti-MUC1 CAR-T Cell Therapy (Guangzhou Anjie Biomedical Technology): Value Creation Analysis (USD Million)
Table 14.1. KYMRIAH®: Drug Overview
Table 14.2. YESCARTA®: Drug Overview
Table 15.1. Autolus: Company Profile
Table 15.2. bluebird bio: Company Profile
Table 15.3. CARsgen Therapeutics: Company Profile
Table 15.4. Celgene: Company Profile
Table 15.5. Cell Medica: Company Profile
Table 15.6. Cellectis: Company Profile
Table 15.7. Cellular Biomedicine Group: Company Profile
Table 15.8. Innovative Cellular Therapeutics: Company Profile
Table 15.9. Kite Pharma: Company Profile
Table 15.10. Noile-Immune Biotech: Company Profile
Table 15.11. Novartis: Company Profile
Table 15.12. Shanghai Genechem: Company Profile
Table 15.13. Sinobioway Cell Therapy: Company Profile
Table 15.14. Takara Bio: Company Profile
Table 15.15. ZIOPHARM Oncology: Company Profile
Table 18.1. CAR-T Cell Therapies: Analysis by Type of Developer
Table 18.2. CAR-T Cell Therapies: Analysis by Phase of Development
Table 18.3. CAR-T Cell Therapies: Analysis by Target Therapeutic Area
Table 18.4. CAR-T Cell Therapies: Analysis by Popular Target Indications
Table 19.5. CAR-T Cell Therapies: Analysis by Target Antigen
Table 18.6. CAR-T Cell Therapies: Analysis by Source of T-Cells
Table 18.7. CAR-T Cell Therapies: Analysis by Route of Administration
Table 18.8. CAR-T Cell Therapies: Analysis by Patient Segment
Table 18.9. CAR-T Cell Therapies: Analysis by Type of Therapy
Table 18.10. CAR-T Cell Therapies: Active Industry Players by Number of Therapies in Clinical Development
Table 18.11. CAR-T Cell Therapies: Active Industry Players by Number of Therapies in Preclinical Development
Table 18.12. CAR-T Cell Therapies: Active Non-Industry Players by Number of Therapies in Clinical Development
Table 18.13. CAR-T Cell Therapies: Active Non-Industry Players by Number of Therapies in Preclinical Development
Table 18.14. CAR-T Cell Therapies: Popular Targets in Hematological Cancer
Table 18.15. CAR-T Cell Therapies: Popular Targets in Solid Tumor
Table 18.16. CAR-Construction: Analysis by Generation of CAR-T Therapies
Table 18.17. CAR-Construction: Analysis by Type of scFv Antibody used in CAR-T Therapies
Table 18.18. CAR-Construction: Analysis by Type of Vector
Table 18.19. CAR-Construction: Analysis by Type of Co-Stimulatory Domain(s)
Table 18.20. CAR-T Cell Therapy Clinical Trials: Distribution by Trial Registration Year
Table 18.21. CAR-T Cell Therapy Clinical Trials: Distribution by Number of Clinical Trials and Geography (Pre-2016 and 2019)
Table 18.22. Overall CAR-T Cell Therapies Market, 2019-2030: Conservative Scenario (USD Billion)
Table 18.23. Overall CAR-T Cell Therapies Market, 2019-2030: Base Scenario (USD Billion)
Table 18.24. Overall CAR-T Cell Therapies Market, 2019-2030: Optimistic Scenario (USD Billion)
Table 18.25. CAR-T Cell Therapies Market: Distribution by Target Indication(s) (USD Billion)
Table 18.26. CAR-T Cell Therapies Market: Distribution by Target Antigen(s) (USD Billion)
Table 18.27. CAR-T Cell Therapies Market: Key Players (USD Billion)
Table 18.28. CAR-T Cell Therapies Market: Distribution by Geography (USD Billion)
Table 18.29. KYMRIAH® (Novartis) Sales Forecast, till 2030: Conservative Scenario (USD Million)
Table 18.30. KYMRIAH® (Novartis) Sales Forecast, till 2030: Base Scenario (USD Million)
Table 18.31. KYMRIAH® (Novartis) Sales Forecast, till 2030: Optimistic Scenario (USD Million)
Table 18.32. YESCARTA® (Gilead Sciences) Sales Forecast, till 2030: Conservative Scenario (USD Million)
Table 18.33. YESCARTA® (Gilead Sciences) Sales Forecast, till 2030: Base Scenario (USD Million)
Table 18.34. YESCARTA® (Gilead Sciences) Sales Forecast, till 2030: Optimistic Scenario (USD Million)
Table 18.35. bb2121 (bluebird bio / Celgene) Sales Forecast, till 2030: Conservative Scenario (USD Million)
Table 18.36. bb2121 (bluebird bio / Celgene) Sales Forecast, till 2030: Base Scenario (USD Million)
Table 18.37. bb2121 (bluebird bio / Celgene) Sales Forecast, till 2030: Optimistic Scenario (USD Million)
Table 18.38. LCAR-B38M CAR-T (Nanjing Legend Biotech / Janssen) Sales Forecast, till 2030: Conservative Scenario (USD Million)
Table 18.39. LCAR-B38M CAR-T (Nanjing Legend Biotech / Janssen) Sales Forecast, till 2030: Base Scenario (USD Million)
Table 18.40. LCAR-B38M CAR-T (Nanjing Legend Biotech / Janssen) Sales Forecast, till 2030: Optimistic Scenario (USD Million)
Table 18.41. MB-CART19.1 (Miltenyi Biotec) Sales Forecast, till 2030: Conservative Scenario (USD Million)
Table 18.42. MB-CART19.1 (Miltenyi Biotec) Sales Forecast, till 2030: Base Scenario (USD Million)
Table 18.43. MB-CART19.1 (Miltenyi Biotec) Sales Forecast, till 2030: Optimistic Scenario (USD Million)
Table 18.44. CD19 CAR-T (Sinobioway Cell Therapy) Sales Forecast, till 2030: Conservative Scenario (USD Million)
Table 18.45. CD19 CAR-T (Sinobioway Cell Therapy) Sales Forecast, till 2030: Base Scenario (USD Million)
Table 18.46. CD19 CAR-T (Sinobioway Cell Therapy) Sales Forecast, till 2030: Optimistic Scenario (USD Million)
Table 18.47. JCAR017 (Juno Therapeutics / Celgene / WuXi AppTec) Sales Forecast, till 2030: Conservative Scenario (USD Million)
Table 18.48. JCAR017 (Juno Therapeutics / Celgene / WuXi AppTec) Sales Forecast, till 2030: Base Scenario (USD Million)
Table 18.49. JCAR017 (Juno Therapeutics / Celgene / WuXi AppTec) Sales Forecast, till 2030: Optimistic Scenario (USD Million)
Table 18.50. AUTO2 (Autolus) Sales Forecast, till 2030: Conservative Scenario (USD Million)
Table 18.51. AUTO2 (Autolus) Sales Forecast, till 2030: Base Scenario (USD Million)
Table 18.52. AUTO2 (Autolus) Sales Forecast, till 2030: Optimistic Scenario (USD Million)
Table 18.53. AUTO3 (Autolus) Sales Forecast, till 2030: Conservative Scenario (USD Million)
Table 18.54. AUTO3 (Autolus) Sales Forecast, till 2030: Base Scenario (USD Million)
Table 18.55. AUTO3 (Autolus) Sales Forecast, till 2030: Optimistic Scenario (USD Million)
Table 18.56. GPC3 CAR-T (Shanghai GeneChem) Sales Forecast, till 2030: Conservative Scenario (USD Million)
Table 18.57. GPC3 CAR-T (Shanghai GeneChem) Sales Forecast, till 2030: Base Scenario (USD Million)
Table 18.58. GPC3 CAR-T (Shanghai GeneChem) Sales Forecast, till 2030: Optimistic Scenario (USD Million)
Table 18.59. BCMA CAR-T (The Beijing Pregene (ShenZhen) Biotechnology) Sales Forecast, till 2030: Conservative Scenario (USD Million)
Table 18.60. BCMA CAR-T (The Beijing Pregene (ShenZhen) Biotechnology) Sales Forecast, till 2030: Base Scenario (USD Million)
Table 18.61. BCMA CAR-T (The Beijing Pregene (ShenZhen) Biotechnology) Sales Forecast, till 2030: Optimistic Scenario (USD Million)
Table 18.62. CD19 CAR-T (The Beijing Pregene (ShenZhen) Biotechnology) Sales Forecast, till 2030: Conservative Scenario (USD Million)
Table 18.63. CD19 CAR-T (The Beijing Pregene (ShenZhen) Biotechnology) Sales Forecast, till 2030: Base Scenario (USD Million)
Table 18.64. CD19 CAR-T (The Beijing Pregene (ShenZhen) Biotechnology) Sales Forecast, till 2030: Optimistic Scenario (USD Million)
Table 18.65. CD19 CAR-T (Shanghai Bioray Laboratory) Sales Forecast, till 2030: Conservative Scenario (USD Million)
Table 18.66. CD19 CAR-T (Shanghai Bioray Laboratory) Sales Forecast, till 2030: Base Scenario (USD Million)
Table 18.67. CD19 CAR-T (Shanghai Bioray Laboratory) Sales Forecast, till 2030: Optimistic Scenario (USD Million)
Table 18.68. Humanized CD19 CAR-T (Shanghai Unicar-Therapy Bio-medicine Technology) Sales Forecast, till 2030: Conservative Scenario (USD Million)
Table 18.69. Humanized CD19 CAR-T (Shanghai Unicar-Therapy Bio-medicine Technology) Sales Forecast, till 2030: Base Scenario (USD Million)
Table 18.70. Humanized CD19 CAR-T (Shanghai Unicar-Therapy Bio-medicine Technology) Sales Forecast, till 2030: Optimistic Scenario (USD Million)
Table 18.71. PCAR-019 (PersonGen BioTherapeutics) Sales Forecast, till 2030: Conservative Scenario (USD Million)
Table 18.72. PCAR-019 (PersonGen BioTherapeutics) Sales Forecast, till 2030: Base Scenario (USD Million)
Table 18.73. PCAR-019 (PersonGen BioTherapeutics) Sales Forecast, till 2030: Optimistic Scenario (USD Million)
Table 18.74. TBI-1501 (Takara Bio) Sales Forecast, till 2030: Conservative Scenario (USD Million)
Table 18.75. TBI-1501 (Takara Bio) Sales Forecast, till 2030: Base Scenario (USD Million)
Table 18.76. TBI-1501 (Takara Bio) Sales Forecast, till 2030: Optimistic Scenario (USD Million)
Table 18.77. IM19 CAR-T Cell Therapy (Beijing Immunochina Medical Science & Technology) Sales Forecast, till 2030: Conservative Scenario (USD Million)
Table 18.78. IM19 CAR-T Cell Therapy (Beijing Immunochina Medical Science & Technology) Sales Forecast, till 2030: Base Scenario (USD Million)
Table 18.79. IM19 CAR-T Cell Therapy (Beijing Immunochina Medical Science & Technology) Sales Forecast, till 2030: Optimistic Scenario (USD Million)
Table 18.80. CCT301 CAR-T (Shanghai Sinobioway Sunterra Biotech) Sales Forecast, till 2030: Conservative Scenario (USD Million)
Table 18.81. CCT301 CAR-T (Shanghai Sinobioway Sunterra Biotech) Sales Forecast, till 2030: Base Scenario (USD Million)
Table 18.82. CCT301 CAR-T (Shanghai Sinobioway Sunterra Biotech) Sales Forecast, till 2030: Optimistic Scenario (USD Million)
Table 18.83. BinD19 (Shenzhen BinDeBio) Sales Forecast, till 2030: Conservative Scenario (USD Million)
Table 18.84. BinD19 (Shenzhen BinDeBio) Sales Forecast, till 2030: Base Scenario (USD Million)
Table 18.85. BinD19 (Shenzhen BinDeBio) Sales Forecast, till 2030: Optimistic Scenario (USD Million)
Table 18.86. CARCIK-CD19 (Formula Pharmaceuticals) Sales Forecast, till 2030: Conservative Scenario (USD Million)
Table 18.87. CARCIK-CD19 (Formula Pharmaceuticals) Sales Forecast, till 2030: Base Scenario (USD Million)
Table 18.88. CARCIK-CD19 (Formula Pharmaceuticals) Sales Forecast, till 2030: Optimistic Scenario (USD Million)
Table 18.89. EGFR CART (The Beijing Pregene Science and Technology) Sales Forecast, till 2030: Conservative Scenario (USD Million)
Table 18.90. EGFR CART (The Beijing Pregene Science and Technology) Sales Forecast, till 2030: Base Scenario (USD Million)
Table 18.91. EGFR CART (The Beijing Pregene Science and Technology) Sales Forecast, till 2030: Optimistic Scenario (USD Million)
Table 18.92. Anti-MUC1 CAR-T (Guangzhou Anjie Biomedical Technology) Sales Forecast, till 2030: Conservative Scenario (USD Million)
Table 18.93. Anti-MUC1 CAR-T (Guangzhou Anjie Biomedical Technology) Sales Forecast, till 2030: Base Scenario (USD Million)
Table 18.94. Anti-MUC1 CAR-T (Guangzhou Anjie Biomedical Technology) Sales Forecast, till 2030: Optimistic Scenario (USD Million)
Table 18.95. CAR-T Cell Therapy Market Forecast, 2019, 2025 and 2030: Conservative, Base and Optimistic Scenarios (USD Billion)
The following companies / institutes / government bodies and organizations have been mentioned in this report.
The USD 11 billion (by 2030) financial opportunity within the CAR-T cell therapy market has been analyzed across the following segments:
Discounts available for multiple report purchases
sales@rootsanalysis.com